OPA1 and cardiomyopathy: Homozygous null mutations of OPA1 are embryonic lethal.9 The heterozygote had slow development of cardiomyopathy, characterized by reduced fractional shortening, markedly reduced inotropy, abnormal calcium transients, mitochondrial dysfunction leading to reduced ATP levels, decreased antioxidant gene expression, and increased ROS.